Epigallocatechin gallate (EGCG), a catechin found in green tea, has been extensively studied for its potential health benefits, particularly in cancer. EGCG exhibits anti-proliferative, anti-angiogenic, and pro-apoptotic effects in various cancer cell lines and animal models. It targets multiple cancer hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evasion of immune destruction. This review highlights the effects of EGCG on these cancer-related hallmarks, providing a foundation for further research and clinical investigations into EGCG as a potential anticancer treatment. EGCG's pharmacokinetic properties and bioavailability are discussed, including its absorption, distribution, and metabolism. Despite its promising anticancer effects, EGCG has shown toxicity in certain doses, particularly in the liver and kidneys. The review also explores the mechanisms by which EGCG targets and inhibits various cancer hallmarks, such as genomic instability, induction of apoptosis, tumorigenesis, sustained proliferative signaling, evasion of anti-growth signaling, replicative immortality, tumor-dysregulated metabolism, tumor-promoting inflammation, angiogenesis inhibition, tissue invasion and metastasis, and tumor-associated immune evasion. The review concludes that EGCG is a promising natural compound with multifaceted therapeutic potential against cancer. However, more clinical studies are needed to fully evaluate its safety and efficacy in treating various malignancies.Epigallocatechin gallate (EGCG), a catechin found in green tea, has been extensively studied for its potential health benefits, particularly in cancer. EGCG exhibits anti-proliferative, anti-angiogenic, and pro-apoptotic effects in various cancer cell lines and animal models. It targets multiple cancer hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evasion of immune destruction. This review highlights the effects of EGCG on these cancer-related hallmarks, providing a foundation for further research and clinical investigations into EGCG as a potential anticancer treatment. EGCG's pharmacokinetic properties and bioavailability are discussed, including its absorption, distribution, and metabolism. Despite its promising anticancer effects, EGCG has shown toxicity in certain doses, particularly in the liver and kidneys. The review also explores the mechanisms by which EGCG targets and inhibits various cancer hallmarks, such as genomic instability, induction of apoptosis, tumorigenesis, sustained proliferative signaling, evasion of anti-growth signaling, replicative immortality, tumor-dysregulated metabolism, tumor-promoting inflammation, angiogenesis inhibition, tissue invasion and metastasis, and tumor-associated immune evasion. The review concludes that EGCG is a promising natural compound with multifaceted therapeutic potential against cancer. However, more clinical studies are needed to fully evaluate its safety and efficacy in treating various malignancies.